# Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

> **NCT06958484** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The Affiliated Hospital of Xuzhou Medical University** · enrollment: 60 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma
- Adjuvant Treatment

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab

## Key facts

- **NCT ID:** NCT06958484
- **Lead sponsor:** The Affiliated Hospital of Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06958484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06958484, "Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06958484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*